Abstract: Methods and compositions for detecting tau pathology are described. The compositions for detecting tau pathology comprise a targeting ligand that specifically binds to a cell surface marker of tau pathology, wherein the targeting ligand is linked to a liposome that includes an imaging agent. The compositions can be used in a method for imaging tau pathology in a subject that comprises administering to the subject an effective amount of the composition to a subject and imaging at least a portion of the subject to determine if that portion of the subject exhibits tau pathology. The compositions can also be used to detect tau pathology in biological samples obtained from a subject.
Abstract: Provided herein are compositions, systems, and methods for minimally-invasive assessment of toxicity-induced tissue injury. In particular, external (e.g., whole-body) scanning is employed to detect toxicity-induced injuries, such as those caused by chemotherapeutics.
Abstract: The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The system includes a computing device, a power supply, one or more sensors, and at least one tracer agent that fluoresces when exposed to electromagnetic radiation. The electromagnetic radiation is detected using the sensors, and the rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.
Type:
Grant
Filed:
October 26, 2018
Date of Patent:
March 14, 2023
Assignee:
MediBeacon Inc.
Inventors:
Martin P. Debreczeny, Raghavan Rajagopalan, Richard B. Dorshow, William L. Neumann, Thomas E. Rogers
Abstract: The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The method includes administering a pyrazine compound of Formula I to a patient and monitoring the rate in which the kidneys of the patient eliminate the pyrazine from the systemic circulation of the patient. The pyrazine compound fluoresces when exposed to electromagnetic radiation which is detected using one or more sensors. The rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.
Type:
Grant
Filed:
October 26, 2018
Date of Patent:
February 28, 2023
Assignee:
MediBeacon Inc.
Inventors:
Raghavan Rajagopalan, Richard B. Dorshow, William L. Neumann, Thomas E. Rogers, Martin P. Debreczeny
Abstract: The invention relates to a nicotine oral delivery product containing a powder enclosed in a water insoluble pouch, wherein said pouch is permeable for saliva and therein dissolved parts of the powder, wherein said powder comprising at least a) nicotine selected from the group consisting of tobacco, nicotine salts, nicotine base, stabilized nicotine, and mixtures thereof corresponding to 0.1 to 20 mg nicotine in the form of nicotine base and b) a chewing gum composition and a method of producing said nicotine oral delivery product.
Type:
Grant
Filed:
March 25, 2013
Date of Patent:
February 28, 2023
Inventors:
Frank Svandal, Per Gunnar Nilsson, Robert Ericsson
Abstract: Provided herein are nanoparticle compositions (e.g., nanoparticle compositions comprising high atomic number ions) that are useful for imaging diseases in a subject as well as radiosensitizing a disease in a subject (e.g., radiosensitizing a cancer in the subject). Methods of imaging a subject, methods of treating cancer, and processes of preparing the nanoparticle compositions are also provided.
Type:
Grant
Filed:
December 8, 2017
Date of Patent:
February 28, 2023
Assignees:
The Brigham and Women's Hospital, Inc., NH TherAguix, Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique
Inventors:
Ross Berbeco, Eloise Thomas, Francois Lux, Olivier Tillement, Alexandre Detappe, Geraldine Le Duc
Abstract: The present inventors have developed new radiolabeled Darapladib and analogs thereof which can be used for the specific detection of vulnerable atherosclerotic plaques by targeting lipoprotein-associated phospholipase A2 (Lp-PLA2) which is a biomarker of choice concerning inflammation and atherosclerosis progression. Thus, the present invention relates to radiolabeled Darapladib and analogs thereof and their use as imaging compounds.
Type:
Grant
Filed:
September 26, 2018
Date of Patent:
February 21, 2023
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE LA REUNION
Abstract: Compositions comprising high levels of high specific activity copper-64, and process for preparing said compositions. The compositions comprise from about 2 Ci to about 15 Ci of copper-64 and have specific activities up to about 3800 mCi copper-64 per microgram of copper. The processes for preparing said compositions comprise bombarding a nickel-64 target with a low energy, high current proton beam, and purifying the copper-64 from other metals by a process comprising ion exchange chromatography or a process comprising a combination of extraction chromatography and ion exchange chromatography.
Type:
Grant
Filed:
August 24, 2022
Date of Patent:
February 14, 2023
Assignee:
Curium US LLC
Inventors:
David Pipes, Lauren Radford, William Uhland, Brian Regna, Craig Brunkhorst
Abstract: Macrocyclic chelators for chelation of alpha-emitting radiometal ions, such as actinium-225 are provided. Also provided are radiometal complexes containing an alpha-emitting radiometal ion bound to the macrocyclic chelator via coordinate bonding, and radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or antigen binding fragment thereof. The radioimmunoconjugates can be produced by click chemistry reactions. Methods of using the radiocomplexes and radioimmunoconjugates for selectively targeting neoplastic cells for radiotherapy and for treating neoplastic diseases and disorders are also described.
Type:
Grant
Filed:
May 8, 2020
Date of Patent:
February 14, 2023
Assignee:
JANSSEN BIOTECH, INC.
Inventors:
Rhys Salter, Vadim Dudkin, Fengbin Song, Wei Zhang, Shalom Goldberg, John Keith
Abstract: The present invention provides the methods of synthesis of [5]helicene compounds and the use of the said compounds conjugating with biomolecules to work as molecular reporter for diagnostic. The compounds in the present invention have the chemical structure illustrated in the formula (1): wherein G is a connecting group composes of 2 carbon atoms selected from the group consisting of ethane and ethylene; A is a separated or connected group selected from the group consisting of cyano and imide; D1 is selected from the group consisting of oxyalkanoic acid, oxyalkanal and oxyalkanesulfonate; and D2 has structure selected from the group consisting of hydroxyl, oxyalkanoic acid, oxyalkanal, alkyl oxyalkanoate, oxyalkanol and oxyalkanesulfonate. The compounds in the present invention compose of aromatic [5]helicene core comprising long it-conjugating system.
Type:
Grant
Filed:
September 29, 2017
Date of Patent:
February 14, 2023
Assignee:
National Science and Technology Development Agency
Abstract: A diagnostic contrast composition includes a carrier fluid and a non-decaying gas-evolving fluid incorporated in the carrier fluid. The gas-evolving fluid has a vapor pressure sufficient to evolve the gas from a circulatory system within a lung of a patient. The gas-evolving fluid is a composition containing a sufficient quantity of atoms with an atomic number higher than 8 to provide an increased absorption sufficient to increase a Hounsfield Unit measurement in an image in a CT imaging system. The gas-evolving fluid is selected from the group consisting of xenon gas, krypton gas, sulfur hexafluoride, a perfluorocarbon, a brominated perfluorocarbon, and combinations thereof. The carrier fluid is selected from the group consisting of water, saline, saline comprising one or more blood proteins, and saline comprising dissolved lipids.
Abstract: Provided is a bilirubin derivative-based ultrasound contrast agent for diagnosis and treatment. The fine particles including the bilirubin derivative are sensitive to reactive oxygen species (ROS), bind with hydrophobic drugs, and can effectively chelate metals such as iron oxide nanoparticles. Therefore, the fine particle of the present invention can be used as an ultrasound contrast agent for diagnosis, as a magnetic resonance imaging contrast agent, or as a carrier for hydrophobic drugs or platinum-based drugs.
Type:
Grant
Filed:
August 4, 2020
Date of Patent:
February 7, 2023
Assignee:
Bilix Co., Ltd.
Inventors:
Sang Yong Jon, Dong Yun Lee, Yong Hyun Lee, Jin Yong Kim
Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.
Type:
Grant
Filed:
September 9, 2019
Date of Patent:
January 31, 2023
Assignee:
Sloan-Kettering Institute for Cancer Research
Inventors:
David A. Scheinberg, Michael R. McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jon Njardarson, Mark Reid Phillips
Abstract: The present invention provides a method for the synthesis of an injectable composition comprising a [18F]-labelled pyridaben derivative that is advantageous over prior methods. In particular, the method of the present invention comprises a method of radiosynthesis that permits a more facile purification using solid phase extraction (SPE).
Type:
Grant
Filed:
March 29, 2019
Date of Patent:
January 31, 2023
Assignee:
GE HEALTHCARE LIMITED
Inventors:
Torgrim Engell, Alexander Jackson, Imtiaz Ahmed Khan, Alan Peter Clarke, Graeme McRobbie, Julian Grigg
Abstract: The present invention provides a method of imaging a subject's lung which comprises contacting the subject's lung with a matrix metalloproteinase inhibitor labeled with a radioisotope under conditions such that the inhibitor binds to matrix metalloproteinase in the lung, and then imaging the radiolabeled inhibitor bound to matrix metalloproteinase in the subject's lung. The invention also provides Ro 32-3555 labeled with a radioisotope.
Type:
Grant
Filed:
May 19, 2017
Date of Patent:
January 31, 2023
Assignee:
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Abstract: Borylated Amino Acid (“BAA”) compositions and methods of making BAAs are disclosed herein. Consequently, the BAAs can be administered to patients as a Neutron Capture Agent and provide a method of treating cancer, immunological disorders and other disease by utilizing a Neutron Capture Therapy modality.
Type:
Grant
Filed:
March 4, 2020
Date of Patent:
January 31, 2023
Assignee:
TAE Life Sciences, LLC
Inventors:
Michael Y. Torgov, Tioga J. Martin, Arthur B. Raitano
Abstract: Embodiments of the present disclosure pertain to methods of opening a lipid bilayer by associating the lipid bilayer with a molecule that includes a moving component capable of moving (e.g., rotating) in response to an external stimulus; and exposing the molecule to an external stimulus before, during or after associating the molecule with the lipid bilayer. The exposing causes the moving component of the molecule to move and thereby open the lipid bilayer (e.g., by pore formation). The external stimuli may include an energy source, such as ultraviolet light. The opened lipid bilayer may be a component of cell membranes in vitro or in vivo. The opening of the lipid bilayer may allow for the passage of various materials (e.g., active agents, such as peptide-based drugs) through the lipid bilayer and into cells. Additional embodiments of the present disclosure pertain to the aforementioned molecules for opening lipid bilayers.
Type:
Grant
Filed:
April 16, 2021
Date of Patent:
January 31, 2023
Assignees:
William Marsh Rice University, Durham University
Inventors:
James M. Tour, Robert Pal, Victor García López, Lizanne Nilewski
Abstract: Provided herein are compounds useful for imaging granzyme B. An exemplary compound provided herein is useful as a radiotracer for position emission tomography (PET) and/or single photon emission tomography (SPECT) imaging. Methods of imaging granzyme B, combination therapies, and kits comprising the granzyme B imaging agents are also provided.
Type:
Grant
Filed:
June 30, 2017
Date of Patent:
January 24, 2023
Assignee:
The General Hospital Corporation
Inventors:
Umar Mahmood, Benjamin Larimer, Eric Wehrenberg-Klee